Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04008225
Other study ID # 35RC15_9885
Secondary ID
Status Completed
Phase
First received
Last updated
Start date May 5, 2015
Est. completion date May 5, 2016

Study information

Verified date July 2019
Source Rennes University Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Firstly, the study assesses the effect of bronchoalveolar lavage fluid (BAL) from patients in (acute respiratory distress syndrome (ARDS) on the life span of PNNs and on the phagocytosis of apoptotic cells by macrophages and polynuclear neutrophil (PNN).

Then, the effect of an antibody directed against "high-mobility group box 1" protein (HMGB1) and the effect of metformin on efferocytosis are studied.


Description:

ARDS (acute respiratory distress syndrome) is a syndrome that causes significant mortality and morbidity. This syndrome is characterized by an alveolitis with polynuclear neutrophil (PNN). PNNs play an important role in the persistence and in injuries induced by ARDS. Several animal studies have shown that lesional edema can be increased by two important mechanisms: the increase in the lifespan of PNNs in the lung and the decrease in the phagocytosis capacities of apoptotic cells (efferocytosis) by macrophages and PNNs.

However, confirmation of these data in humans does not exist, and knowledge of the mechanisms that may increase lung damage during ARDS will limit it and thus reduce the mechanical ventilation time of these patients as well as the mortality associated with ARDS.

" high-mobility group box 1 " (HMGB1) protein may be involved in reducing efferocytosis capacity. Similarly, activation of AMP-activated protein kinase (AMPk) could restore the clearance capacity of apoptotic cells in macrophages and PNNs.


Recruitment information / eligibility

Status Completed
Enrollment 42
Est. completion date May 5, 2016
Est. primary completion date May 5, 2016
Accepts healthy volunteers
Gender All
Age group N/A and older
Eligibility Inclusion Criteria:

- ARDS Group : Inpatients hospitalized in medical intensive care with an ARDS defined according to the Berlin criteria and requiring an BAL(for diagnostic purpose in suspicion of pneumopathy acquired under mechanical ventilation).

- Control group : The control population is made up with patients with a BAL considered normal (endoscopy patients from the pneumology department). The normality of the BAL is defined by a normocellular wash with cellularity: < 150,000 to 200,000 cells/mL Cell composition (formula): macrophages: 80-90%, lymphocytes 5 to 10% (< 20%), neutrophils: < 5%, eosinophils: < 2%.

Exclusion Criteria:

- Age < 18 years;

- Pregnant women ;

- Persons deprived of their liberty by judicial or administrative decision;

- Persons legally incapable;

- Persons not affiliated to a social security system;

- Previously immunocompromised patients (HIV infection, hematopathy, organ transplantation, immunosuppression);

- Patients who do not require a lung sample.

Study Design


Related Conditions & MeSH terms


Intervention

Procedure:
Bronchoalveolar lavage


Locations

Country Name City State
France CHU de Rennes Rennes

Sponsors (1)

Lead Sponsor Collaborator
Rennes University Hospital

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Lifespan of the PNNs The lifespan of the PNNs is an indicator of apoptosis : two groups are compared with and without incubation in BAL fluid.
Neutrophil necrosis was assessed by flow cytometry using a phycoerythrin-conjugated active caspase-3 apoptosis kit (Becton Dickinson, USA)
24 hours after BAL
Secondary PNNs phagocytic index This index relates the ability of the PNNs to produce neutrophil extracellular traps (NETs).
The release of NETs was quantified by measuring fluorescence with a microplate fluorescence reader (Varioskan, ThermoFisher Scientific, USA).
24 hours after BAL
Secondary Efferocytosis index The efferocytosis index was determined on 300 cells as the percentage of Human monocyte-derived macrophages (HMDMs) containing at least one ingested apoptotic neutrophil. 24 hours after BAL
Secondary Increase of PNNs phagocytic index with HMGB1 activator PNNs phagocytic index is measured after incubation with an anti-HMGB1 neutralising antibody 24 hours after BAL
Secondary Increase of Efferocytosis index metformin efferocytosis index was determined after incubation with an AMP-activated protein kinase (AMPK) activator (metformin) 24 hours after BAL
See also
  Status Clinical Trial Phase
Not yet recruiting NCT06444750 - Comparison of the Proteome in ICU Patients in Search for TRALI Biomarkers
Not yet recruiting NCT05306392 - Effects of Induced Moderate Hypothermia on ARDS Patients Under Venovenous ExtraCorporeal Membrane Oxygenation N/A
Completed NCT04274296 - Advisory Lead ARDS Respirator Management
Completed NCT04719182 - Practice of Adjunctive Treatments in Intensive Care Unit Patients With COVID-19
Terminated NCT04954014 - Pilot Study of Single Dose Bevacizumab as Treatment for Acute Respiratory Distress Syndrome (ARDS) in COVID-19 Patients Phase 2
Recruiting NCT03215316 - Screening Expiratory Flow Limitation by Flow-time Curve N/A
Recruiting NCT04115514 - Treatment of ARDS With Instilled T3 Phase 2
Not yet recruiting NCT05061212 - The Mechanism of Extracellular Vesicles Containing Mitochondrial DNA in ARDS Lung Injury Caused by Extrapulmonary Sepsis
Not yet recruiting NCT04556864 - Hemodynamic Impact on Critical Care Patients With Lung Damage Secondary to COVID-19
Completed NCT05693051 - Use of Prone Position Ventilation in Danish Patients With COVID-19 Induced Severe ARDS Treated With VV-ECMO
Recruiting NCT04174014 - Optimal PEEP Titration Combining Transpulmonary Pressure Measurement and Electric Impedance Tomography N/A
Enrolling by invitation NCT06164639 - Potential Biomarkers for Reflux Aspiration-induced Lung Injury.
Terminated NCT05384379 - Efficacy and Safety Evaluation of BZ371B in ARDS Patients Early Phase 1
Completed NCT04375735 - London's Exogenous Surfactant Study for COVID19 Phase 1/Phase 2
Completed NCT06224010 - Respiratory Drive and Inspiratory Effort in COVID-19 Associated ARDS
Not yet recruiting NCT04530188 - Effects of Sevoflurane on Extravascular Lung Water and Pulmonary Vascular Permeability in Patients With ARDS Phase 3
Completed NCT03405038 - Prone Position Impact in ARDS Patients on the Incidence of Central Venous Catheter Colonization
Recruiting NCT05148026 - Regional Citrate Anticoagulation for RRT During V-V ECMO N/A
Recruiting NCT04390360 - Smartphone Application for Initiation of Protective Ventilation. Clinical Impact of Instrumental Dead Space Reduction N/A
Completed NCT06197256 - Cardiac Dysfunction in Critically Ill Covid-19 Patients